Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 14. Online ahead of print. doi: 10.1016/j.tibtech.2023.05.007

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Authors

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Schematic overview of replicon delivery vehicles.

(A) In trans coexpression of replicon RNA and helper RNAs in a mammalian production cell line enables encapsulation of replicon RNA in virus-like replicon particles. Delivery vehicles can also be based on nonviral carriers that encapsulate the replicon RNA in (B) liposomes, (C) lipid nanoparticles, or (D) nanostructured lipid carriers in a cell-free manufacturing process. The delivery vehicles protect the replicon RNA and allow efficient delivery to target cells upon immunization.